Gallic-Natamycin

N/A

Report date: 2026/03/06 20:02:51
NME

Base Information

Drug NameGallic-Natamycin
Drug Alias NameGA-NATGA-NAT
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionOxidized low-density lipoprotein receptor 1 inhibitorsTumor necrosis factor α inhibitorsInterleukin-1 beta inhibitors +[4] 
TargetsOxidized low-density lipoprotein receptor 1Tumor necrosis factor αInterleukin-1 beta +[4] 
Therapy Area/IndicationsKeratitisMycoses
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesN/A
China Registration ClassN/A

Develop Information

Active CompaniesWayne State University School of MedicineUniversity Of WashingtonQingdao University
Inactive CompaniesN/A
Active IndicationsKeratitisMycoses
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A